Evidence map›Paper›PMID 32936523›Full record

ReviewJournal of the International AIDS Society2020

HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates.

Soo-Yon Rhee, Seble G Kassaye, Geoffrey Barrow, Jagadish Chandrabose Sundaramurthi, Michael R Jordan, Robert W Shafer

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06044792 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in Patients Treated With Antiretroviral Drugs - an Observational Cohort Study.

TypeobservationalSponsorMedical University of WarsawRan2023 to 2028Enrolled50ConditionsHiv, AIDS, CD4 Deficiency, ARTArmsdifferences in CD4 reconstruction
NCT06661317 unknown statusnot on this mapstarted 2024, after this paper: background citation

Presence of HIV-1 DRMs As a Risk Factor of Failure of Two Drugs Based ART Regimens, Including LAI ART, in Cohorts of Primary and Secondary DRMs.

TypeobservationalSponsorMedical University of WarsawRan2024 to 2024Enrolled200ConditionsHIV-1-infection, DRM, DRM Gene Mutation, ARTArmsno intervention
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Soo-Yon RheeDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-1231-6542
Seble G KassayeDepartment of Medicine, Georgetown University, Washington, DC, USA.
Geoffrey BarrowDepartment of Medicine, Faculty of Medical Science, University of the West Indies, Mona, Jamaica.ORCID 0000-0002-0784-9440
Jagadish Chandrabose SundaramurthiDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6670-9157
Michael R JordanDivision of Geographic Medicine, Tufts Medical Center, Boston, MA, USA.
Robert W ShaferDepartment of Medicine, Stanford University, Stanford, CA, USA.
Stanford University · USGeorgetown University · USTufts University · USUniversity of the West Indies System · JM

Funding

Institutional Career Development CoreKL2TR001432 · NCATS · GEORGETOWN UNIVERSITY · PI UMANS, JASON G · 2015 to 2024
$7.5M
HIV Drug Resistance DatabaseR24AI136618 · NIAID · STANFORD UNIVERSITY · PI ROBERT William SHAFER · 2018 to 2026
$7.3M
NCATS NIH HHS KL2 TR001432NIAID NIH HHS AI136618NIAID NIH HHS R24 AI136618
6 · The paper itself

Abstract

introductionHIV-1 transmitted drug resistance (TDR) prevalence increased during the initial years of the antiretroviral therapy (ART) global scale-up. Few studies have examined recent trends in TDR prevalence using published genetic sequences and described the characteristics of ART-naïve persons from whom these published sequences have been obtained.

methodsWe identified 125 studies published between 2014 and 2019 for which HIV-1 reverse transcriptase (RT) with or without protease from ≥50 ART-naïve adult persons were submitted to the GenBank sequence database. The population characteristics and TDR prevalence were compared to those in 122 studies published in the preceding five years between 2009 and 2013. TDR prevalence was analysed using median study-level and person-level data. RESULTS AND DISCUSSION: The 2009 to 2013 and 2014 to 2019 studies reported sequence data from 32,866 and 41,724 ART-naïve persons respectively. Studies from the low- and middle-income country (LMIC) regions in sub-Saharan Africa, South/Southeast Asia and Latin America/Caribbean accounted for approximately two-thirds of the studies during each period. Between the two periods, the proportion of studies from sub-Saharan Africa and from South/Southeast Asia countries other than China decreased from 43% to 32% and the proportion of studies performed at sentinel sites for recent HIV-1 infection decreased from 33% to 22%. Between 2014 and 2019, median study-level TDR prevalence was 4.1% in South/Southeast Asia, 6.0% in sub-Saharan Africa, 9.1% in Latin America/Caribbean, 8.5% in Europe and 14.2% in North America. In the person-level analysis, there was an increase in overall, NNRTI and two-class NRTI/NNRTI resistance in sub-Saharan Africa; an increase in NNRTI resistance in Latin America/Caribbean, and an increase in overall, NNRTI and PI resistance in North America.

conclusionsOverall, NNRTI and dual NRTI/NNRTI-associated TDR prevalence was significantly higher in sub-Saharan Africa studies published between 2014 and 2019 compared with those published between 2009 and 2013. The decreasing proportion of studies from the hardest hit LMIC regions and the shift away from sentinel sites for recent infection suggests that global TDR surveillance efforts and publication of findings require renewed emphasis.

Indexed as

Drug Resistance, ViralAfricaAnti-HIV AgentsAsiaHIV-1HIV InfectionsHumansPrevalenceAnti-HIV Agentsantiretroviral therapydrug resistanceHIV-1proteasereverse transcriptasesurveillance

Identifiers

PMID32936523
PMCPMC7507012
OpenAlexW3085432332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.